home About Us People Portfolio News Contact Us Fund I Investor Login » Fund II Investor Login » Fund III Investor Login »


Mar22Capital Royalty Strengthens Royalty Investment Team With Three New Appointments

Houston, TX - March 22, 2010 – Capital Royalty L.P. (“Capital Royalty”) announced today that it continues to expand and strengthen its royalty investment team with three new appointments – Andrei Dorenbaum as General Counsel and Executive Director, Peter Faroni as Associate, and James Tate as Analyst. Mr. Dorenbaum will operate out of the Firm’s Houston headquarters, while Messrs. Faroni and Tate will join Mike Weinmann in the Firm’s New York office.


As Capital Royalty’s General Counsel and Executive Director, Mr. Dorenbaum brings over fifteen years of legal and transaction experience, most recently as Assistant General Counsel at Highland Capital Management, L.P. – a registered investment advisor with over $20 billion under management. While at Highland Capital, Mr. Dorenbaum completed over $2 billion in negotiated investments and structured derivative financing arrangements and worked extensively with Nate Hukill in structuring biopharmaceutical royalty bond purchases. Prior to his position with Highland Capital, Mr. Dorenbaum acted as a Managing Director at the NASD/NASDAQ/AMEX group overseeing the Corporate Ventures Group that was responsible for direct investments in financial services related companies. Mr. Dorenbaum also was a corporate attorney with Baker & McKenzie.


Joining Capital Royalty as an Associate, Mr. Faroni brings four years of investing and capital markets experience, most recently as an Associate in Morgan Stanley's Special Situations Group where he focused on distressed debt and event-driven credit opportunities. Prior to that, Mr. Faroni was part of Morgan Stanley’s Global Capital Markets division where he worked with Mike Weinmann on biopharmaceutical royalty bond offerings as well as on structured debt financings of aircraft. Mr. Faroni received his B.A. in Economics and Mathematics from Middlebury College, graduating magna cum laude.


Mr. Tate interned as an analyst with Capital Royalty, L.P. in New York City prior to joining the firm as a full-time Analyst. In his first year at Capital Royalty, Mr. Tate assisted in the development of the firm’s proprietary relationship management database and continues to provide proprietary research that helps the team identify and prioritize royalty leads. Mr. Tate received his B.A. from New York University, graduating magna cum laude.


“Our stated goal is to strengthen and position Capital Royalty for market leadership in healthcare investing for the future. Our plan is three-fold:  assemble a world-class investment team that unites the finest pioneers and innovators in healthcare financing; sharpen our collective vision to enhance our competitive market advantage; and, refine our royalty investment strategy to attract the highest-quality IP assets through the design of innovative royalty financing structures,” said Charles W. Tate, Capital Royalty Founder and Chairman.


“We continue to build a world-class royalty investment team of the finest talent in healthcare financing. Mr. Dorenbaum’s legal experience bolsters an already robust capability in originating and structuring royalty bonds. Messrs. Faroni and Tate add significant support to Mike Weinmann’s New York royalty investment team. Together, the Capital Royalty team has managed over $4.2 billion in healthcare assets and completed over 50 royalty transactions representing $3.7 million in capital over the past 15 years,” Mr. Tate concluded.



Founded in 2003, Capital Royalty L.P. is a market pioneer and innovator in healthcare investing with a focus on intellectual property investments in FDA-approved biopharmaceutical assets through royalty bond and other royalty monetization structures. Collectively, the Capital Royalty investment team has more than 140 years of healthcare, capital markets, private equity and investment banking experience, having completed more than 50 royalty transactions representing $3.7 billion in capital over the past fifteen years. Capital Royalty focuses on sourcing, structuring and investing in healthcare royalty monetization transactions that target attractive risk-adjusted returns with superior downside protection for investors. The Firm is headquartered in Houston, Texas with offices in New York, New York and Boulder, Colorado. For further information, please visit www.capitalroyalty.com.